Cellenkosincis A Clinical Stage Biotechnology Company Based In Houstontexasfounded In 2016The Company Specializes In Developing Allogeneic T Regulatorytregcell Therapies Aimed At Treating Autoimmune Diseases And Inflammatory Disorderscellenkos Leverages Cord Blood Derived Treg Cells To Restore Immune Balancefocusing On Conditions Such As Lupusmultiple Sclerosisand Crohnae S Disease The Company Utilizes Its Proprietary Craneaplatform For The Enrichment And Differentiation Of Treg Cellsensuring Effective Cell Expansion And Targeted Delivery To Inflamed Tissuescellenkos Operates An In House Cgmp Manufacturing Facilityallowing For Comprehensive Control Over Production And Compliance With Regulatory Standardsits Lead Productck0801Is Designed To Replace Defective Tregs In Patientsdemonstrating Strong Anti Inflammatory Propertiescellenkos Is Committed To Addressing Rare Inflammatory Diseases Through Innovative Cell Based Treatmentswith A Pipeline That Includes Therapies For Conditions Like Rheumatoid Arthritis And Bone Marrow Failure Syndromes
